Skip to content

A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis (PRIDE)

A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis (PRIDE). A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis (PRIDE). This study has been completed. PRIDE (an Open-Label Access PRogram to Evaluate the Safety and Effectiveness of Adalimumab When Added to InaDEquate Therapy for the Treatment of Psoriasis) was a multicentre, Phase IIIb study in Canada.

A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis (PRIDE) 2A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis. Methods PRIDE (an Open-Label Access PRogram to Evaluate the Safety and Effectiveness of Adalimumab When Added to InaDEquate Therapy for the Treatment of Psoriasis) was a multicentre, Phase IIIb study in Canada. Open Access. Published primary studies evaluating the efficacy of switching TNF antagonists after failure were systematically extracted. There was no common definition of treatment failure across these studies of varied design.

When Added to Inadequate Therapy for the Treatment of Psoriasis ( PRIDE). A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis. Sponsors: Abbott. Phases: Phase III. Indications, Acronym: PRIDE. Psoriasis. Age Groups: Adult; Senior. When Added to Inadequate Therapy for the Treatment of Psoriasis (PRIDE) W10-151 / Abbott Laboratories Ltd.

Drug Spider

A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis (PRIDE) 3Patients from REVEAL could enter an open-label extension trial to receive adalimumab for approximately 3 years of total therapy. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study.

Loading